Literature DB >> 15158926

Quality of life in schizophrenics with and without the deficit syndrome.

R Gourevitch1, S Abbadi, J D Guelfi.   

Abstract

We investigated the relations between deficit as part of schizophrenic symptomatology and the popular but unclear concept of quality of life (QOL). In a 47-patient sample, subjective QOL was compared in schizophrenics with and without the deficit syndrome. Self- and hetero-rated QOL is more impaired in deficit patients. Differences between deficit and non-deficit groups are more significant as the index used for measuring QOL gets less "behavioral" and more "psycho-pathological". These results are consistent with existing literature. The "behavioral" dimensions of Heinrichs' quality of life scale (QLS) are less discriminative between deficit and non-deficit schizophrenics, but they are more independent of the symptoms. They might have a special clinical meaning, which needs to be defined. The concepts of QOL (as used in QLS) and deficit symptomatology are partially redundant. QLS might be an inappropriate, or at least un-specific measure of QOL.

Entities:  

Mesh:

Year:  2004        PMID: 15158926     DOI: 10.1016/j.eurpsy.2003.08.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  3 in total

1.  Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial.

Authors:  Ahmed Mahmoud; Karen P Hayhurst; Richard J Drake; Shôn W Lewis
Journal:  Schizophr Res Treatment       Date:  2011-01-16

2.  Associated factors of quality of life in first-episode schizophrenia patients.

Authors:  Yun Young Song; Kyung Ran Kim; Jin Young Park; Su Young Lee; Jee In Kang; Eun Lee; Suk Kyoon An; Jun Soo Kwon
Journal:  Psychiatry Investig       Date:  2011-08-26       Impact factor: 2.505

3.  Validity of subjective versus objective quality of life assessment in people with schizophrenia.

Authors:  Karen P Hayhurst; Jennifer A Massie; Graham Dunn; Shôn W Lewis; Richard J Drake
Journal:  BMC Psychiatry       Date:  2014-12-24       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.